Istiratumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Istiratumab Usage And Synthesis

Uses

Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].

References

[1] Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. DOI:10.1016/j.annonc.2019.09.004
[2] Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. DOI:10.1158/1078-0432.CCR-17-2262
[3] Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832. DOI:10.1038/s41598-019-53322-y

Istiratumab(1509928-04-4)Related Product Information

• Ezabenlimab
• Idarucizumab
• Mitumomab
• Telimomabaritox
• Tavolimab
• Indatuximab Ravtansine
• Erfonrilimab
• Ozoralizumab
• Relfovetmab
• Navivumab